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Abstract
Tolerance to the analgesic effect of opioids is the major concern of long-term administration of these
compounds. In this study, the effects of hydroalcoholic extract of Vitex agnus-castus (VAC) on the acquisition
and expression of morphine-induced tolerance were evaluated in mice by tail-flick test. To evaluate the VAC
effects on the development or expression of morphine tolerance, animals received VAC (i.p.), 30 min before
morphine (50 mg/kg; s.c.) during induction period once daily for 3 days; or 30 min before challenge dose of
morphine (5 mg/kg) before (day 1) and after morphine-induced tolerance (day 4), respectively. The analgesic
effect of VAC was evaluated every 30 min till 2 h. VAC at the doses of 120 and 180 mg/kg could suppress the
development of tolerance. In addition, VAC at the dose of 180 mg/kg attenuated the expression of
morphine-induced tolerance. While, the VAC alone had no analgesic effect, its combination with morphine at
the dose of 180 mg/kg, could significantly enhance the antinociceptive effect of morphine. VAC can
attenuate the expression of morphine’s tolerance. Based on the enhancement of the analgesic effect of
morphine’s challenge dose by VAC, it seems that the expression is more attenuated by additive effect of VAC
than reversal of tolerance. The ability of VAC to ameliorate the acquisition and expression of morphine-
induced tolerance in mice may be worthwhile for traditional chronic pains treatment in combination with
opioids without concern of tolerance and dependence.
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Introduction
The long-term efficacy of opioids, like morphine, is
often limited by the development of tolerance to
their analgesic effect. As a consequence, opioid
monotherapy may result an inadequate analgesia.
Regarding to the multiplicities mechanisms which
are involved in the pain, [1] the opioids tolerance
could be overcome by combination of opioids with
one or more non-opioid analgesics to obtain a more
favorable balance of analgesia. Recently, herbal
medicines have attracted more attention for several
advantages including more safety compliance and
less expense. Vitex agnus-castus (VAC) known as
vitagnus or chaste tree is a deciduous shrub and is
native to the Mediterranean Europe and central
Asia. This plant had been well known in Iranian
ancient medical schools and Alkandi used this plant
for the treatment of epilepsy and psychosis in 1200
A.D. [2] Traditionally, VAC fruit extract has been
widely used for the treatment of many female
disorders, such as menstrual irregularity,
premenstrual syndrome (PMS) and cyclic mastalgia.
[3, 4] In addition, VAC has been used to treat pain,
swelling, inflammation, headaches, rheumatism,
and sexual dysfunction. Although further rigorous
studies are needed to assess the safety of VAC, the
available data indicates that VAC is a safe herbal
medicine. [2] The major compounds of VAC are
Casticin, Luteolin, Rotundifuran and Agnuside. [5]
The dopaminergic effects of VAC extract have been
proven in animal models and clinical trials. [6, 7] In
vitro investigations have elucidated that the
lipophilic extract acts as agonist for mu and kappa
opioid and D2 dopaminergic receptors, [8] while
aqueous fraction has more tendency to bind with
delta opioid receptors. [9] On the other hand,
dopamine has been implicated in the acquisition of
tolerance to the opioid induced analgesia. [10,11] It
has been suggested that activation of opioid
receptors located on dopaminergic neurons in the
striatum and nucleus accumbens [12] may play an
important role in the development of tolerance and
sensitization to the opiates. [13] Based on the
dopaminergic effects and additional
pharmacological actions of VAC extract via opioid
receptors, the aim of the study was to evaluate the
possible effects of VAC extract on the acquisition
and expression of tolerance to the morphine-
induced antinociception in tail-flick model of pain in
mice.
Methods
The adult male NMRI mice (Pasteur Institute, Iran)
weighing 20–30 g were maintained on a 12/12-h
light/dark cycle (lights on at 07:00 h) and constant
temperature (22±2 °C). Animals were allowed free
access to food and water except during the
experiments. The animals were acclimatized to the
set up for a 45-min prior to the experiments and all
experiments were conducted between 14:00 and
17:00 h, during the light portion of the cycle. Animals
were allowed free access to food and water except
during the experiments. All experiments were
executed with the Guide for the Care and Use of
Laboratory Animals (National Institute of Health
Publication No. 80-23, revised 1996) and were
approved by the Research and Ethics Committee of
Shahid Beheshti University; M.C. Efforts were made
to minimize the number and potential suffering of
experimental subjects.
The tail-flick test was used for evaluating the
antinociception and acquisition of morphine
tolerance. The latency to withdraw the tail from a
feedback-controlled projector lamp focused on the
dorsal surface of tail was used as a measure of
nociceptive responsiveness. Tail-flick latency (TFL)
more than 8 (s) was considered as a cut-off point to
avoid any tissue damage. To determine the baseline
latency, two tail-flick tests were done before the pre
and post tests for each mouse and the average of
them considered as baseline latency. TFL times (s)
are expressed as percentage of maximal possible
effect (%MPE) using the equation:
The animals were rendered tolerant to the morphine
using the method by a previous study on the
induction of morphine tolerance in mice. [14]
Morphine was purchased from Temad Daru
Company of Iran. Firstly, the antinociceptive
response to a challenge dose of morphine (5 mg/kg;
s.c.) was determined by tail-flick test at 30-min
intervals (0.5, 1, 1.5 and 2 h) on day 1 (n = 7-8 in
each group). Then the tolerance induction was begun
on day 1 by administration of morphine (50 mg/kg;
s.c.) once daily for 3 days. To evaluate the acquisition
of tolerance to the morphine’s antinociception, the
response to the challenge dose was determined
again for each mouse on day 4 as post-test as cited
above. The challenge dose of morphine was selected
as already described by Chavooshi et al. (2009). [15]
The hydro-alcoholic extract of VAC was prepared by
Sina Daru Company of Iran. To evaluate the effects of
VAC on the induction of morphine’s tolerance,
animals (n = 7-8) received various doses of VAC (60,
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120 or 180 mg/kg; i.p.), 30-min before morphine
(50 mg/kg; s.c.) or vehicle once daily for 3
consecutive days. The effect of the challenge dose
of morphine (5 mg/kg; s.c.) was tested prior to (day
1) and following the induction period of morphine
tolerance (day 4) at different time set intervals as
cited above. The doses of VAC were selected as
described previously. [16] To assess the effects of
VAC on the expression of morphine-induced
tolerance, the animals (n = 7-8) received different
doses of VAC (60, 120 or 180 mg/kg; i.p.) or vehicle
30-min before challenge dose of morphine (5
mg/kg) following morphine-induced tolerance (on
day 4). The antinociceptive response to the
challenge dose of morphine for each animal was
determined by tail-flick test on day 4 (post-
tolerance induction) at different time set intervals,
as described above.
The antinociceptive effect of various single doses of
VAC (60, 120 or 180 mg/kg; i.p.) alone or its vehicle
(control) were determined at different time set
intervals (0.5, 1, 1.5 and 2 h), 30-min post injection.
Also, the analgesic response of the VAC in
combination with morphine (5 mg/kg; s.c.) was
determined as cited above. The animals (n = 7-8)
received either VAC or vehicle, 30-min prior to
morphine injection. All obtained data were
analyzed using the GraphPad Prism software
(version 5.0) and presented as mean ± SEM
(standard error of mean). The mean of %MPEs in all
groups were subjected to two-way analysis of
variance (ANOVA) followed by Bonferroni’s test as a
post test. P values less than 0.05 were considered
to be statistically significant.
Results
The antinociceptive response to the challenge dose
of morphine (5 mg/kg; s.c.) for both vehicle and
pre-tolerant groups on day 1 had no difference at
all time set of intervals (Fig. 1A). To assess the
morphine’s tolerance, the animals received
morphine (50 mg/kg) or vehicle (10 ml/kg) once
daily for 3 days. Two-way ANOVA indicated that the
antinociceptive response (the mean of %MPEs
values) to the challenge dose of morphine on day 4
decreased significantly in morphine-treated animals
that received morphine during the induction period
in comparison with the vehicle-treated group
[F(1,48)=54.2, P<0.0001; Fig. 1B] at all time set
intervals. These findings are clearly indicative of the
acquisition of tolerance to the morphine-induced
antinociception following 3 days of morphine
treatment. To evaluate the effects of VAC on the
induction of morphine’s tolerance, the animals
received different doses of VAC (60, 120 or 180
mg/kg; i.p.), 30-min before morphine (50 mg/kg; s.c.)
administration once daily for 3 days during the
induction period. The obtained data revealed that
pretreatment of animals with VAC significantly
reduced the acquisition of tolerance to morphine
antinociceptive effect in a dose-dependent manner,
as indicated by increment of %MPE in VAC treatment
groups. However, the lowest dose of VAC (60 mg/kg)
had no effect on the acquisition of morphine
tolerance. Two-way ANOVA followed by Bonferroni’s
test indicated that in morphine-treated animals
which received either 120 or 180 mg/kg of VAC prior
to the morphine injection during the induction
period, the antinociceptive responses to the
challenge dose of morphine (5 mg/kg; s.c.) on day 4
were increased significantly in comparison to control
group [F(3,96)=11.37, P<0.0001; Figure 2].
We evaluated then whether a single dose of VAC
prior to the challenge dose of morphine (tolerance
expression) was sufficient or daily administration of
VAC was necessary to inhibit the morphine
tolerance. Thus, the animals received VAC (60, 120
or 180 mg/kg; i.p.) or vehicle (10 ml/kg; i.p.), 30-min
before challenge dose of morphine (5 mg/kg) prior to
and following morphine-induced tolerance. Data
analysis indicated that VAC at the dose of 180 mg/kg
attenuated the expression of morphine tolerance
[F(3,96)=62.33, P<0.0001; Figure 3] at all-time set
intervals. To determine the antinociceptive effect of
VAC alone, the tail-flick test were done at 0.5, 1, 1.5
and 2 h after single injection of different doses of the
VAC (60, 120 or 180 mg/kg; i.p.). As shown in Fig. 4,
two-way ANOVA indicated that there was no
significant difference between analgesic effects
(MPEs) of various doses of VAC alone when
compared to those of the vehicle group
[F(3,96)=0.116, P=0.9513; Figure 4]. In addition, to
evaluate the effects of VAC on morphine-induced
antinociception, the animals received various doses
of VAC (60, 120 or 180 mg/kg; i.p.), 30-min before
morphine (5 mg/kg; s.c.) injection. Data analysis
showed that the co-administration of VAC at the
dose of 180 mg/kg with morphine (5 mg/kg)
significantly increased the %MPE in comparison to
the morphine alone treated group [F(3,96)=10.58,
P<0.0001; Figure 5].
Discussion
The present study showed that while VAC alone has
no antinociceptive effect in the tail-flick test, as an
acute pain model, it could suppress the acquisition of
morphine tolerance. In addition, VAC enhanced the
antinociceptive effect of morphine and attenuates_______________________________________
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the expression of tolerance to the antinociceptive
effect of morphine. Morphine and related opioid
drugs produce potent analgesia by activating
specific receptors associated with spinal and brain
neurons involved in nociceptive signaling. [17]
Chronic administration of these drugs, however,
produces a state of tolerance, indicated by the loss
of drug potency. In clinical situations, the
consequence of the opioid induced tolerance is
escalation of drug dose and limitation of the opioids
efficacy in the management of severe pain
syndromes. [18]
The major finding of this study suggests that the
VAC pretreatment can inhibit the acquisition of
morphine tolerance, dose-dependently. One
common possible mechanism of tolerance
development suggests opioid receptors
involvement during chronic opioid administration.
[19] Consistent with this mechanism, VAC may
affect the opiate systems including μ, δ, and κ
opiate receptors and endogenous opiate peptides
such as β-endorphin. [7] Meier et al. (2000) have
reported that an ethanolic and several subfractions
of a methanolic extracts of VAC show affinity for
opiate receptors. [6] On the other hand, the opioid
system has close functional links to the
dopaminergic system in several areas, including the
substantia nigra, mesocortex and mesolimbic
projections. [20] Previous studies have suggested
that D2 dopamine agonists could attenuate opioid
tolerance. [11] Moreover, opioids are known to
modulate dopamine release in a variety of brain
areas. [20] Some properties of opioids, including
hyperlocomotion and reward, are at least partly
mediated through dopamine receptors. [21] Also,
morphine has increased the metabolism of
dopamine in the septum and nucleus accumbence.
[22] In addition, several studies have indicated that
VAC acts on dopamine D2 receptors. [6, 8]
Moreover, previous studies showed that steroid
hormones influence female rat’s response to
noxious stimuli. [23, 24] Nociception varies across
the estrous cycle. [25] Proestrous rats, with high
concentration of estradiol and progesterone, have
shown more latency to tail-flick and paw flick in
response to radiant heat, compared to diestrous
rats that have low hormone levels. [26] Also, it had
been shown that administration of estradiol
compared to vehicle, increased latencies in
response to the heat stimuli. [27] It has also been
suggested that some elements in the VAC extract
may act on the estrogen (ER-β) receptors. [28] The
estrogenic effects of VAC extract maybe related to
the presence of linoleic acid as an estrogenic
compound. [5] Liu et al. (2004)] [28] have suggested
that linoleic acid from the fruits of VAC can bind to
estrogen receptors and induce certain estrogen
inducible genes. So, this mechanism also may be
involved in the VAC extract effects on morphine
tolerance but more investigations are needed to
elucidate the precise mechanism. We showed that
VAC alone has no antinociceptive effect, Our results
are in consistent with the report of Ravishankar et al.
(1985) who failed to observe the analgesia from
ethanolic extract of Vitex-negundo (another species
of Vitex) in tail-flick method. [29] In contrast, Gupta
and Tandon (2005) had shown that Vitex-negundo
produced a significant antinociception in the
experimental models such as tail-flick test and acetic
acid induced writhing. [30] This discrepancy might be
attributed to the different experimental situations as
they used rats for tail-flick test, low dose of acetic
acid (0.6%) in writhing test and applied higher doses
of Vitex-negundo (100-500 mg/kg) in their study.
In the other set of our experiments, we showed that
VAC enhances morphine’s antinociceptive effects in
tail-flick test. As cited above, the interaction of VAC
with opioid receptors and dopaminergic system may
contribute to the latter effect. As a result, co-
administration of drugs such as VAC with morphine
which can produce therapeutic analgesia with lower
dose of morphine would be of great clinical
implication. It has been previously reported that the
acquisition and expression of morphine-induced
tolerance are distinct phases. [31] Our results
indicate that VAC can attenuate the expression of
morphine’s tolerance. Based on the enhancement of
the analgesic effect of morphine’s challenge dose by
VAC, it seems that the expression is more attenuated
by additive effect of VAC than reversal of tolerance.
In conclusion, based on the present study, while VAC
can suppress both the acquisition and expression of
morphine-induced tolerance, VAC has no analgesic
effect alone. To elucidate the mechanisms involved
in these observed effects further investigation are
warranted.
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Figure 1. Acquisition of tolerance to morphine-
induced antinociception; The effect of challenge
dose (5 mg/kg; s.c.) of morphine, (A) before
tolerance induction on day 1 and, (B) following
3 consecutive days administration of vehicle 10
ml/kg (○) or morphine 50 mg/kg (●) as an
induction period on day 4. Each point
represents the mean ± SEM of percent of
maximal possible effect (%MPE) for 7-8 mice.
***P<0.001 in comparison to the vehicle-
treated group
Figure 2. The effect of different doses of Vitex
agnus-castus (VAC) on the development of
morphine tolerance. Animals received VAC (60,
120 or 180 mg/kg; i.p.) or vehicle (10 ml/kg; i.p.),
30-min before morphine (50 mg/kg; s.c.) once
daily for 3 days during the induction period. In
the day 4, the tail-flick latencies were
determined after injection of challenge dose of
morphine (5 mg/kg; s.c.). Each point represents
the mean ± SEM for 7-8 mice.
*P<0.05, ** P<0.01, ***P<0.001 in comparison
to the vehicle group
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Figure 4. The antinociceptive effects of
different doses of Vitex agnus-castus (VAC)
alone presented as the percent of maximal
possible effect (%MPE). The animals received
VAC (60, 120 or 180 mg/kg), 30-min before
morphine administration. Each point is the
mean ± SEM for 7-8 mice.
Figure 5. The antinociceptive effects of different
doses of Vitex agnus-castus (VAC) in
combination with morphine present as the
percent of maximal possible effect (%MPE). The
animals received VAC (60, 120 or 180 mg/kg),
30-min before the morphine injection (i.p.). Each
point is the mean ± SEM for 7-8 mice.
** P<0.01; *** P<0.001 in comparison to the
morphine-treated group
Figure 3. The effect of different doses of Vitex
agnus-castus (VAC) on the expression of
morphine-induced tolerance. Following 3 days
of morphine tolerance induction (50 mg/kg;
once daily). Various doses of VAC or vehicle
were administered 30-min prior to injection of
challenge dose of morphine (5 mg/kg; s.c.) at
day 4. Each point is the mean ± SEM of percent
of maximal possible effect (%MPE) for 7-8
mice.
†, * indicates significant in comparison to the
morphine-treated (tolerant) and vehicle
treated (non-tolerant) groups, respectively,
P<0.05, ††† or *** P<0.001
